由Akkermansia muciniphila进行的GDNF信号调制改善了帕金森病中便秘-抑郁症并发症
Chunyan Mu1,2,3, Zairen Zhou4, Jingyu Li3,5
1Department of Neurology, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
NPJ Parkinson's disease
|November 28, 2025
概括
帕金森病的便秘和抑郁症源于肠-大脑通信受损. 肠道质细胞 (EGC) 功能障碍驱动这种情况,但质细胞衍生神经营养因子 (GDNF) 和益生菌具有治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
背景情况:
- 便秘和抑郁是帕金森病 (PD) 的常见非运动症状.
- 在PD中连接这些症状的潜在共享机制仍然不太清楚.
- 肠道质细胞 (EGCs) 在肠-大脑轴中起着至关重要的作用,影响肠道运动和情绪.
研究的目的:
- 阐明将EGC功能障碍与帕金森病中便秘和抑郁症联系在一起的分子机制.
- 确定治疗这些非运动症状的潜在治疗点.
- 研究TLR4/NEDD4/CX43信号通路在PD相关便秘和抑郁症 (PD-CD) 中的作用.
主要方法:
- 研究了肠质细胞 (EGC) 中的TLR4/NEDD4/CX43信号轴.
- 在细胞中评估ATP释放和血清素 (5-HT) 合成.
- 利用质细胞衍生神经营养因子 (GDNF) 和Akkermansia muciniphila Akk11 (Akk11) 作为PD小鼠模型中的干预措施.
- 研究了对肠道运动性和抑郁现象型的影响.
主要成果:
- 在EGC中异常的TLR4激活导致持续的ATP释放,通过NEDD4/CX43通路损害EC细胞中的5-HT合成.
- 这种ATP介导的纯能毒性导致PD相关的便秘和抑郁症.
- 在小鼠中,GDNF和Akk11益生菌治疗恢复了EGC功能,使5-HT水平正常化,并缓解了PD-CD症状.
- 为PD-CD建立了一个"EGC-EC轴"模型.
结论:
- EGC-EC轴为帕金森病,便秘和抑郁症提供了一个统一的机制.
- 以GDNF为中心的策略和Akk11等特定益生菌显示出治疗PD非运动症状的希望.
- 向EGC功能障碍为PD提供了一个潜在的多目标治疗方法.
相关概念视频
01:24Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
857
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
857